Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Neoplasms
Interventions: DRUG: Capivasertib|DRUG: Paclitaxel|DRUG: Placebo
Sponsor: AstraZeneca